Cargando…

Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report

Major disease complications for patients with essential thrombocythemia (ET) include thrombosis and fibrotic or leukemic transformation. Calreticulin (CALR) mutation type 1 frequencies in ET are estimated between 7% and 11% and ET patients carrying CALR type 1 mutation are associated with lower risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morsia, E, Goteri, G, Torre, E, Garvey, KB, Discepoli, G, Tassoni, A, Mancini, S, Giantomassi, F, Poloni, A, Olivieri, A, Rupoli, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142272/ https://www.ncbi.nlm.nih.gov/pubmed/34040959 http://dx.doi.org/10.1016/j.lrr.2021.100243

Ejemplares similares

P1045: IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS?
por: Morsia, E., et al.
Publicado: (2022)

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications
por: Morsia, Erika, et al.
Publicado: (2022)

Anticoagulation and Vessel Recanalization in Cirrhotic Patients with Splanchnic Vein Thrombosis: A Multidisciplinary “Real Life” Experience
por: Rupoli, Serena, et al.
Publicado: (2021)

Detecting CALR Mutations in Splanchnic Vein Thrombosis: Who and How?
por: Langabeer, Stephen E.
Publicado: (2018)

Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis
por: Rupoli, Serena, et al.
Publicado: (2015)

A rare case of aCML associated with CNS involvement and with aggressive clinical course
por: Lame, Dorela, et al.
Publicado: (2023)

Invasive ductal breast carcinoma preceded by CALR‐positive essential thrombocythemia
por: Ali, Elrazi A., et al.
Publicado: (2021)

Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia
por: Langabeer, Stephen E., et al.
Publicado: (2016)

Splenic mass in a case of CALR‐mutated essential thrombocythemia
por: Imashuku, Shinsaku, et al.
Publicado: (2018)

Retinal neovascularization in the setting of CALR-mutation positive essential thrombocythemia
por: Heydinger, Stanton P, et al.
Publicado: (2023)

Incidence, Clinical Features, and Prognostic Impact of CALR Exon 9 Mutations in Essential Thrombocythemia and Primary Myelofibrosis: An Experience of a Single Tertiary Hospital in Korea
por: Park, Sang Hyuk, et al.
Publicado: (2015)

Recurrent thrombosis of splanchnic and lower extremity arteries with essential thrombocythemia
por: Jung, Sung Min, et al.
Publicado: (2019)

Splanchnic Vein Thrombosis in Myelofibrosis—An Underappreciated Hallmark of Disease Phenotype
por: Beleva, Elina A.
Publicado: (2023)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
por: Mejía-Ochoa, Mónica, et al.
Publicado: (2019)

Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia
por: Kang, Min-Gu, et al.
Publicado: (2016)

Recent advances in understanding myelofibrosis and essential thrombocythemia
por: Vainchenker, William, et al.
Publicado: (2016)

Primary myelofibrosis with concurrent CALR and MPL mutations: A case report
por: Zhou, Feng-Ping, et al.
Publicado: (2020)

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2023)

Selected Parameters of Angiogenesis and the JAK2, CALR, and MPL Mutations in Patients With Essential Thrombocythemia
por: Gadomska, Grażyna, et al.
Publicado: (2018)

Essential thrombocythemia with CALR mutation and recurrent stroke: two case reports and literature review
por: Chen, Rong, et al.
Publicado: (2022)

Leukocytosis and presence of CALR mutation is associated with non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis
por: Barraco, D, et al.
Publicado: (2016)

Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations
por: Kubuki, Yoko, et al.
Publicado: (2017)

Imatinib Treatment of Chronic Myeloid Leukemia Reveals a Preexisting CALR-mutated Essential Thrombocythemia
por: Blouet, Anaïse, et al.
Publicado: (2018)

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
por: Tefferi, A, et al.
Publicado: (2017)

The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: Conchon, Monika
Publicado: (2011)

The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2016)

Pleomorphic circulating megakaryocytes in a case of CALR positive primary myelofibrosis in leukemic transformation
por: Moshref Razavi, Habib
Publicado: (2021)

CALR type 1 mutations are associated with an increased incidence of myelofibrosis in young male patients
por: Weir, Philip, et al.
Publicado: (2022)

P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
por: Morè, S, et al.
Publicado: (2022)

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles
por: Zini, Roberta, et al.
Publicado: (2017)

Unusual presentation of primary myelofibrosis with spontaneous bleeding after laparoscopic adrenalectomy: A case report
por: Colozzi, Sara, et al.
Publicado: (2020)

Myocardial Infarction as an Initial Presentation of Essential Thrombocythemia With Calreticulin (CALR) Mutation (None Type 1, None Type 2)
por: Afana, Mohammad, et al.
Publicado: (2023)

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Ogasawara, Ken, et al.
Publicado: (2019)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
por: Carobbio, Alessandra, et al.
Publicado: (2023)

CALR mutation analysis is not indicated in patients with splanchnic vein thrombosis without evidence of a myeloproliferative neoplasm: a micro-review
por: Langabeer, Stephen E.
Publicado: (2016)

Mutations and thrombosis in essential thrombocythemia
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia
por: Ji, Liying, et al.
Publicado: (2017)

Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia
por: Vu, Hoang Anh, et al.
Publicado: (2019)

HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report
por: Krzysztof, Lewandowski, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cdhlo8845s5dq7v8fjruka0rhc